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ABSTRACT
Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are
pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent
ﬁndings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)—which is
genetically linked to PD—promotes cancer progression via redox-mediated inactivation of phosphatase
and tensin homolog (PTEN) by S-nitrosylation.
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Although cancer and Parkinson disease (PD) have opposing
clinical manifestations, the observation that loss of parkin RBR
E3 ubiquitin protein ligase (PRKN, best known as PARK2), also
contributes to cancer progression suggests that additional com-
mon mechanisms may be involved in the progression of both
diseases more so than previously appreciated. PARK2 encodes
the ubiquitin E3 ligase Parkin, and was ﬁrst identiﬁed as a gene
associated with the pathogenesis of early-onset PD,1 but was
later linked with a wide range of disorders, most notably can-
cer, where it is a bona ﬁde haploinsufﬁcient tumor suppressor.2
In our recent study,3 we identiﬁed a novel role for the
PARK2 gene as a negative regulator of the phosphatidylinositol
3-kinase/AKT serine/threonine kinase 1 (PI3K/AKT) pathway,
mediated by phosphatase and tensin homolog (PTEN). We
showed that PARK2 loss at both the DNA copy number and
mRNA expression levels is observed on average in as high as
one in three tumors and it correlates with poorer prognosis.
Our ﬁndings demonstrated that PARK2 depletion leads to a
marked activation of the PI3K/AKT signaling, which is consis-
tent with lower sensitivity to staurosporine-induced cell death
and higher vulnerability to inhibitors of the PI3K/AKT path-
way. In support of our data, Yeo and colleagues previously
reported that ectopic PARK2 expression inhibits AKT activa-
tion, and mitigates cell proliferation and migration in glioma
cells.4 Interestingly, we showed that the genetic background
that faithfully recapitulates these phenotypes was wild-type for
the tumor suppressor PTEN, suggesting that the functional
contribution of PARK2 depletion in the activation of PI3K-
AKT pathway could be mediated, at least in part, by PTEN
inactivation. Indeed, we showed that although PARK2 deple-
tion did not affect PTEN mRNA expression, it led to reduced
PTEN protein levels and most importantly an ablation of its
enzymatic activity, with a concomitant increase in phosphati-
dylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) and phosphati-
dylinositol (3,4)-bisphosphate (PtdIns(3,4)P2) levels.
In light of these data, along with previous compelling evi-
dence that mitochondrial respiration defects lead to enhanced
AKT activation through redox-mediated inactivation of
PTEN,5 we studied the effect of PARK2 depletion on cellular
bioenergetics. Interestingly, PARK2 knockdown cells showed a
signiﬁcant reduction in oxygen consumption rates, which was
consistent with the activation of protein kinase AMP-activated
catalytic subunit a 1 (AMPK) as the cellular energy sensor
responding to adenosine triphosphate (ATP) depletion. PARK2
knockdown also led to a major reduction in the anaplerotic
substrates that contribute to nitric oxide (NO) synthesis, but
with no signiﬁcant difference in L-citrulline. These data,
together with previous evidence that AMPK can directly phos-
phorylate nitric oxide synthase 3 (NOS3, best known as eNOS)
at Ser1177 and Ser6336 enhancing NO bioavailability suggested
that PARK2 loss might play a prominent role in AMPK-medi-
ated activation of eNOS. Indeed, we showed that PARK2 deple-
tion resulted in a marked increase in nitric oxide synthase
(NOS) activity and the production of oxidized NO, leading to
PTEN S-nitrosylation and its enhanced ubiquitin-proteasome
degradation. Last but not least, Park2 monoallelic or biallelic
deletion in mice completely ablated Pten protein expression
and was shown to promote tumor progression in Pten hetero-
zygous knockout mice.
Our study highlights a critical role of nitrosative stress in
regulating the activation of PI3K/AKT signaling (Fig. 1).
Although PTEN appears critically important for this action,
it is likely that there are other PTEN-independent mecha-
nisms contributing to NO-induced activation of pro-survival
signaling pathways. Notably, S-nitrosylation reactions,
unlike in the case of PTEN, result in the activation of epi-
dermal growth factor receptor (EGFR), proto-oncogene
tyrosine-protein kinase Src,7 HRas proto-oncogene, GTPase
(Ras)8 and can also modify hypoxia-inducible factor 1-a
(HIF-1a),9 enhancing its accumulation and activity. Hence,
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PARK2 loss could serve as a valuable biomarker for the
identiﬁcation of redox-dictated activation of oncogenic sig-
naling pathways and ultimately guide the response to inhib-
itors of the aforementioned signaling pathways.
In addition to the induction of NO signaling in the absence
of functional PARK2, an important role for AMPK has also
been deﬁned. AMPK activation is stimulated in response to
metabolic stress conditions, and we showed that it is sufﬁcient
to induce PTEN S-nitrosylation even in the presence of func-
tional PARK2,3 demonstrating a novel functional crosstalk,
whereby AMPK can contribute to AKT activation independent
of its known role in the inhibition of the negative feedback loop
mechanisms mediated by mechanistic target of rapamycin
complex 1 (mTORC1) and ribosomal protein S6 kinase b-1
(S6K1). The role of AMPK, the central cellular metabolic sen-
sor, in cancer is complex, and its potential as a therapeutic tar-
get is controversial. AMPK has been reported to act both as a
tumor suppressor and oncogene based on the speciﬁc genetic,
metabolic, and signaling contexts.10 Our results demonstrate
that AMPK activation can confer the plasticity that cancer cells
require to survive under conditions of metabolic stress through
S-nitrosylation-mediated inhibition of PTEN (Fig. 1). Impor-
tantly, we found that cancer cells expressing the S-nitrosylation
resistant isoform of PTEN (C83S) were signiﬁcantly more sen-
sitive to metabolic stress-inducing drugs 2-Deoxy-glucose
(2-DG) and PDK inhibitor dichloroacetate (DCA),3 both of
which result in the depletion of ATP and concomitant activa-
tion of AMPK. These ﬁndings are highly relevant in the context
of the “biguanide paradox” theory proposed in the ﬁeld based
on reports that cancer cells are more susceptible to cell death
by biguanides metformin, phenformin, or other compounds
that cause metabolic stress [5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR), salicylate, or 2-DG] when used in
combination with agents that inhibit, rather than activate,
AMPK.10
Although the precise implications of enhanced nitrosative
stress and PI3K/AKT activation upon PARK2 loss are likely to
be different between cancer and PD, it is conceivable that they
could promote or hinder cell survival in different disease settings.
This is perhaps not surprising, when the post-mitotic nature of
neuronal cells is considered; e.g. activation of the PI3K/AKT
pathway may provide one means of promoting cell cycle re-entry
in cancer cells, but could lead to the death of terminally differen-
tiated neuronal cells. Moreover, cancer cells can exhibit higher
detoxiﬁcation capacity and/or adapt to oxidative and nitrosative
stress-induced DNA damage, while considerable experimental
evidence supports that the extensive production of reactive
oxygen species (ROS) in the brain is the leading contributor to
dopaminergic neuronal loss in PD.
Together, our data demonstrate that PARK2 depletion contrib-
utes to PI3K/AKT activation via inactivation of PTEN by
S-nitrosylation and provide several lines of evidence supporting
the concept that inhibition of this pathway is important for
PARK2’s function as a tumor suppressor. It is anticipated that fur-
ther studies identifying additional targets of S-nitrosylation might
open up novel therapeutic opportunities for both cancer and PD.
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Figure 1. PARK2 loss connects AMPK-mediated nitrosative stress to PI3K/AKT activation. Parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2) loss prevents
degradation of damaged mitochondria by mitophagy leading to impaired respiration, lower adenosine triphosphate (ATP) levels, and an increase in ROS. Protein kinase
AMP-activated catalytic subunit a 1 (AMPK) gets activated in response to metabolic stress and in turn induces activation of nitric oxide synthase 3 (NOS3, best known as
eNOS), resulting in an increase in nitric oxide (NO) levels and concomitant inactivation of phosphatase and tensin homolog (PTEN) via S-nitrosylation, thereby promoting
the activation of the phosphatidylinositol 3-kinase/AKT serine/threonine kinase 1 (PI3K/AKT) pathway. Other proteins in the pathway that could be the target of aberrant
S-nitrosylation are EGFR and protooncogene tyrosine-protein kinase Src. AMPK can be activated by various additional modulators including (1) Metabolic stress that
depletes ATP; e.g., by hypoxia, oligomycin, 2-Deoxy-glucose (2-DG) and dichloroacetate (DCA); (2) kinases; Serine/threonine-protein kinase STK11 (STK11, best known as
LKB1) and Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2); (3) Pharmacological activators; e.g., 991, Metfor-min and 5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR); and (4) Adipokines; leptin and adiponectin. Metabolic stress-induced AMPK activation was shown to be sufﬁcient to trigger PTEN S-nitrosylation
even in the presence of functional PARK2.
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